A Phase 4 interventional study of Fish oil intervention and Placebo intervention in Obesity and Mild Cognitive Impairment, sponsored by Weiwei Ma. Not yet recruiting. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-06-17.
Sponsored by Weiwei Ma · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Eighty-eight patients with obesity with mild cognitive impairment(MCI) from the Multicenter Nutrition and Chronic Disease Cohort, who met the inclusion and exclusion criteria, were selected as study subjects and randomly divided into 2 groups, i.e., the placebo group and the n-3 PUFA intervention group. Subjects in the intervention group were given supplemental n-3 PUFA (supplied in 1.36 g fish oil capsules); the placebo group took placebo (1.36 g/d), and the intervention period was 12 consecutive months. General information, dietary intake, body composition, exercise, overall cognitive function and multidimensional cognitive function, abundance of Mycobacterium avium and its metabolites acetic acid and propionic acid content, beige adiposity markers, inflammation-related factors, and lipid metabolism were collected at baseline, at the end of 6 months and at the end of 12 months of the intervention, respectively, and the adherence of the two groups of subjects was also assessed. To analyze the effects of n-3 PUFA intervention on cognitive function in patients with obesity with MCI and to explore the possible mechanisms.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
This study's planned enrollment of 88 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Browse Obesity studies →Weiwei Ma is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Placebo intervention
Dietary Supplement: Fish oil intervention
The diet was based on the principles of a balanced diet, and subjects in this group were additionally supplemented with n-3 PUFA (provided as 1.36 g fish oil capsules), with the rest of the intervention being the same as in the control group.
Diet based on the principles of a balanced diet, taking placebo capsules with the same appearance and odor as the fish oil capsules.
Height, Waist
Measurement of the subject's height and waist circumference using a tape measure.
Time frame: Baseline, 6 months, 12 months
weight
The weight of the subjects was measured using a weighing scale.
Time frame: Baseline, 6 months, 12 months
Total Body Water
Measuring Total Body Water (L) with the InBody Body Composition Analyzer.
Time frame: Baseline, 6 months, 12 months
body protein, inorganic salts, and body fat
Measurement of body protein, inorganic salts, and body fat using the InBody Body Composition Analyzer (kg)
Time frame: Baseline, 6 months, 12 months
Appendicular skeletal muscle mass index
Skeletal muscle mass of the extremities is the sum of the muscle mass of both upper and lower extremity skeletal muscles, which was measured using a body composition meter. The appendicular skeletal muscle mass index (ASMI) is the mass of the skeletal muscles of the extremities divided by the square of the height (kg/m2).
Time frame: Baseline, 6 months, 12 months
Cognitive function assessment
Cognitive function was assessed using the Montreal Cognitive Assessment (MoCA) scale, which is a 30-point scale that includes multiple dimensions of cognitive functioning, including visuospatial and executive functioning, naming, memory, attention, language, abstraction, delayed recall, and orientation. The MCI diagnostic criteria were: \<6 years of education, MoCA score ≤19; \>7 years of education but ≤12 years, MoCA ≤22; \>12 years of education, MoCA ≤24.
Time frame: Baseline, 6 months, 12 months
Dietary composition
The food frequency questionnaire (FFQ) was used for the survey assessment. With reference to the FFQ questionnaire used in the Nutrition and Health Status Survey of Chinese Residents, a total of 72 food inquiry entries in 11 food groups were included, with a focus on n-3 PUFA-rich foods, as well as the intake of edible oils and condiments. Auxiliary survey tools such as the Retrospective Dietary Survey Auxiliary Atlas were used to help respondents recall. The Standardized Version of the Chinese Food Composition Table (6th Edition) was used to calculate the energy and nutrient intake of the population, including the intake of dietary fatty acids.
Time frame: Baseline
Dietary Inflammation Index
The dietary inflammatory index (DI) for each dietary component/nutrient was calculated separately for each individual based on the mean and standard deviation of the per capita daily intake of each dietary component or nutrient and the corresponding dietary effect index of each component.If a food increases the level of pro-inflammatory factors or decreases the level of anti-inflammatory factors, it is labeled as "+1" for a pro-inflammatory effect; conversely, it is assigned "-1" for an anti-inflammatory effect. If there was no significant change in inflammatory markers, "0" was assigned as no pro/anti-inflammatory effect. The final DI score for each food was accumulated to obtain an overall dietary DI score for the individual; the higher the total DI score, the greater the pro-inflammatory effect of the diet, and conversely, the greater the anti-inflammatory effect.
Time frame: Baseline
Species and abundance of intestinal flora
Detection Methods:Fecal flora was detected by designing and amplifying sequences specific to B. anthropophilus and then applying RT-qPCR.
Time frame: Baseline, 6 months, 12 months
Metabolite levels of intestinal flora
HPLC-MS/MS
Time frame: Baseline, 6 months, 12 months
Plasma inflammatory factor levels
High-Throughput Liquid Protein Chip
Time frame: Baseline, 6 months, 12 months
Erythrocyte Membrane n-3 PUFA Levels
Gas Chromatography
Time frame: Baseline, 6 months, 12 months
Plasma Beige Lipid Marker Levels
Double antibody sandwich ELISA
Time frame: Baseline, 6 months, 12 months
Fecal Akkermansia abundance
qPCR
Time frame: Baseline, 6 months, 12 months
Fecal Amuc_1100 expression levels
Fecal Amuc_1100 mRNA expression was detected using Realtime-PCR.
Time frame: Baseline, 6 months, 12 months
Detection of signaling pathway related indicators of plasma fat metabolism
Enzyme colorimetric method
Time frame: Baseline, 6 months, 12 months
Levels of lipopolysaccharide
Enzyme colorimetric method
Time frame: Baseline, 6 months, 12 months
Plasma lipid oxide concentrations
LC-MS/MS
Time frame: Baseline, 6 months, 12 months
Levels of fatty acid synthetase
Enzyme colorimetric method
Time frame: Baseline, 6 months, 12 months
Blood lipids
Enzyme colorimetric method
Time frame: Baseline, 6 months, 12 months
Fasting blood glucose
Hexokinase method
Time frame: Baseline, 6 months, 12 months
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Start is estimated for Aug 2025; primary completion for Dec 2026, 16 months later.
Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 16 months is below that.
Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weiwei Ma